Morgan Stanley analyst Terence Flynn raised the firm’s target price in Bristol Myers (BMY) to $40 from $37 and maintains an underweight rating on the stock. 2026 revenue and EPS guidance came in above consensus, but was driven by higher-than-expected Eliquis guidance, the analyst tells investors in a research note.

Claim 50% off TipRanks Premium

• unlock data at the hedge fund level i powerful investment tools to make more intelligent and correct decisions

• Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

Posted first The Fly – The ultimate source of real-time, breaking financial news that moves the market. Try now >>

Check out today’s top performing stocks on TipRanks >>

Read more about BMY:

Disclaimer and DisclosureReport a problem

• trump Trade: Argentina says US will cut hundreds of tariffs

• Bristol Myers’ price target rose to $68 from $64 at BofA

• Bristol Myers’ price target rose to $72 from $62 at Guggenheim

• Bristol Myers’ price target rose to $64 from $60 at Citi

• Bristol Myers’ price target rose to $60 from $55 at Wells Fargo